SNF Point-of-Care Testing: Confirm CLIA Scope Before Connecting Results to the EHR

Confirm the laboratory before the interface

The CMS CLIA application guidance says the certificate must match the highest testing complexity performed. A waived-testing laboratory still needs a director. 42 CFR 493.15(e) requires following manufacturer instructions for waived tests.

Identify the actual testing location, certificate, director, specific test system and intended use. Verify categorization against current authoritative information for that system. Do not infer that all cartridges used on one instrument have the same category or that a facility's general CMS certification replaces CLIA requirements.

Resolve a three-test expansion proposal

A fictional SNF proposes connecting three test workflows to its clinical record. Test A is already performed under the verified certificate and instructions. Test B is a different system whose complexity and site authorization have not been checked. Test C uses a waived system, but the proposed local process changes a manufacturer-specified step.

The team proceeds with technical validation for A after confirming its prerequisites. B remains pending laboratory review of the actual system and certificate scope. C returns to qualified review; the team does not approve the modified process merely because the interface can accept its results.

The result is one technically testable workflow and two unresolved regulatory dependencies. This is an original administrative scenario, not a recommendation of any test or testing procedure.

Trace a corrected result without erasing the first message

For Test A, a synthetic result reaches the correct resident record with the source test identifier, collection and result times, units or qualitative result, and appropriate status. A later authorized correction is then sent. The receiving record must distinguish the corrected result from the original and preserve the reason and history through the approved process.

The test checks that the correction reaches the responsible clinical recipient and any downstream view that used the earlier result. A transport acknowledgment only establishes receipt by a system; it does not prove that the responsible clinician reviewed a material correction. Qualified clinical staff define notification and action requirements.

The nursing-home laboratory-services rule addresses obtaining needed services, authorized requests, prompt notification of results outside clinical reference ranges according to facility policies, and dated laboratory reports that identify the testing laboratory by name and address. The software demonstration must support those duties without inventing clinical thresholds.

Check current program and product changes

The current CMS CLIA page says revised CMS-116 forms are required for initial applications or certificate-information updates starting November 9, 2026, and describes the paperless certificate and fee process. Retain the current certificate and communications route rather than relying on an old paper renewal file.

CMS's October 14, 2026 post-PHE memo also addresses the December 26, 2026 termination of specified SARS-CoV-2 test EUA declarations and conditional continued use aligned with FDA enforcement discretion. That is not a blanket instruction to discard every test or continue every product. The laboratory must verify the actual product, authorized setting, transition conditions and expiration.

The finished readiness record joins certificate scope, approved test instructions, qualified personnel and a corrected-result trace. For a platform buyer, this exposes whether laboratory and clinical workflows remain coherent when a test changes or a result is corrected.